Cadrenal Therapeutics Inc
CVKD7.110USD
-0.260-3.53%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
14.64MMarket Cap
LossP/E TTM
More Details of Cadrenal Therapeutics Inc Company
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative therapeutics to overcome the gaps in anticoagulation therapy. The Company’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The Company also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). It also includes Frunexian, a Phase 2-ready IV Factor XIa agent for acute anticoagulation and EP-7327 is a ready oral small molecule candidate for chronic indications.
Cadrenal Therapeutics Inc Info
Ticker SymbolCVKD
Company nameCadrenal Therapeutics Inc
IPO dateJan 20, 2023
CEOPham (Quang X)
Number of employees4
Security typeOrdinary Share
Fiscal year-endJan 20
Address822 A1a North
CityPONTE VEDRA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code32082
Phone19043000701
Websitehttps://www.cadrenal.com/
Ticker SymbolCVKD
IPO dateJan 20, 2023
CEOPham (Quang X)
Company Executives of Cadrenal Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Quang Pham
Mr. Quang Pham
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
196.09K
-3.65%
Mr. Matthew K. (Matt) Szot, CPA
Mr. Matthew K. (Matt) Szot, CPA
Chief Financial Officer
Chief Financial Officer
9.93K
-47.26%
Dr. Glynn Wilson, Ph.D.
Dr. Glynn Wilson, Ph.D.
Independent Director
Independent Director
3.33K
--
Dr. Lee Golden, M.D.
Dr. Lee Golden, M.D.
Independent Director
Independent Director
--
--
Mr. John R. Murphy
Mr. John R. Murphy
Independent Director
Independent Director
--
--
Dr. Steven Zelenkofske
Dr. Steven Zelenkofske
Independent Director
Independent Director
--
--
Dr. James J. Ferguson, III
Dr. James J. Ferguson, III
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jeffrey (Jeff) Cole
Mr. Jeffrey (Jeff) Cole
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Quang Pham
Mr. Quang Pham
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
196.09K
-3.65%
Mr. Matthew K. (Matt) Szot, CPA
Mr. Matthew K. (Matt) Szot, CPA
Chief Financial Officer
Chief Financial Officer
9.93K
-47.26%
Dr. Glynn Wilson, Ph.D.
Dr. Glynn Wilson, Ph.D.
Independent Director
Independent Director
3.33K
--
Dr. Lee Golden, M.D.
Dr. Lee Golden, M.D.
Independent Director
Independent Director
--
--
Mr. John R. Murphy
Mr. John R. Murphy
Independent Director
Independent Director
--
--
Dr. Steven Zelenkofske
Dr. Steven Zelenkofske
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 7
Updated: Sun, Dec 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The PVBQ Living Trust
8.55%
Pham (Quang X)
8.39%
Armistice Capital LLC
3.36%
Havlickova 648 as
3.35%
The Vanguard Group, Inc.
2.32%
Other
74.03%
Shareholders
Shareholders
Proportion
The PVBQ Living Trust
8.55%
Pham (Quang X)
8.39%
Armistice Capital LLC
3.36%
Havlickova 648 as
3.35%
The Vanguard Group, Inc.
2.32%
Other
74.03%
Shareholder Types
Shareholders
Proportion
Corporation
12.98%
Individual Investor
12.24%
Hedge Fund
4.21%
Investment Advisor
3.14%
Investment Advisor/Hedge Fund
0.66%
Research Firm
0.33%
Other
66.44%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
36
194.75K
4.18%
--
2025Q3
36
194.75K
4.21%
+45.85K
2025Q2
32
146.98K
4.45%
-957.00
2025Q1
28
147.94K
3.86%
+74.17K
2024Q4
22
99.13K
1.44%
+14.84K
2024Q3
16
78.70K
2.01%
+55.29K
2024Q2
15
23.41K
10.61%
-89.81K
2024Q1
14
113.22K
3.52%
+75.62K
2023Q4
11
36.78K
8.50%
-36.96K
2023Q3
10
73.74K
9.99%
-12.98K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The PVBQ Living Trust
200.00K
9.77%
--
--
Jul 28, 2025
Pham (Quang X)
203.51K
9.94%
-9.79K
-4.59%
Sep 29, 2025
Armistice Capital LLC
78.61K
3.84%
+78.61K
--
Sep 30, 2024
Havlickova 648 as
78.29K
3.82%
+11.96K
+18.03%
Dec 31, 2024
The Vanguard Group, Inc.
48.59K
2.37%
+2.96K
+6.49%
Jun 30, 2025
Murphy (John Raymond)
40.99K
2%
--
--
Jul 28, 2025
Geode Capital Management, L.L.C.
12.71K
0.62%
+624.00
+5.16%
Jun 30, 2025
Szot (Matthew K)
18.83K
0.92%
-12.50K
-39.89%
Sep 29, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 16, 2024
Merger
15→1
Aug 16, 2024
Merger
15→1
Aug 16, 2024
Merger
15→1
Aug 16, 2024
Merger
15→1
Date
Type
Ratio
Aug 16, 2024
Merger
15→1
Aug 16, 2024
Merger
15→1
Aug 16, 2024
Merger
15→1
Aug 16, 2024
Merger
15→1
FAQs
Who are the top five shareholders of Cadrenal Therapeutics Inc?
The top five shareholders of Cadrenal Therapeutics Inc are:
The PVBQ Living Trust holds 200.00K shares, accounting for 9.77% of the total shares.
Pham (Quang X) holds 203.51K shares, accounting for 9.94% of the total shares.
Armistice Capital LLC holds 78.61K shares, accounting for 3.84% of the total shares.
Havlickova 648 as holds 78.29K shares, accounting for 3.82% of the total shares.
The Vanguard Group, Inc. holds 48.59K shares, accounting for 2.37% of the total shares.
The PVBQ Living Trust holds 200.00K shares, accounting for 9.77% of the total shares.
Pham (Quang X) holds 203.51K shares, accounting for 9.94% of the total shares.
Armistice Capital LLC holds 78.61K shares, accounting for 3.84% of the total shares.
Havlickova 648 as holds 78.29K shares, accounting for 3.82% of the total shares.
The Vanguard Group, Inc. holds 48.59K shares, accounting for 2.37% of the total shares.
What are the top three shareholder types of Cadrenal Therapeutics Inc?
The top three shareholder types of Cadrenal Therapeutics Inc are:
The PVBQ Living Trust
Pham (Quang X)
Armistice Capital LLC
The PVBQ Living Trust
Pham (Quang X)
Armistice Capital LLC
How many institutions hold shares of Cadrenal Therapeutics Inc (CVKD)?
As of 2025Q4, 36 institutions hold shares of Cadrenal Therapeutics Inc, with a combined market value of approximately 194.75K, accounting for 4.18% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.03%.
What is the biggest source of revenue for Cadrenal Therapeutics Inc?
In --, the -- business generated the highest revenue for Cadrenal Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
